6 active not recruiting, 1 withdrawn. 7 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Active not recruiting 6, Withdrawn 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Elimusertib: new trials by email Literature Review of Elimusertib trials Research Report on Elimusertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Biospecimen Collection, Computed Tomography, Elimusertib - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 7 | 2022-07-06 | 2026-08-21 |
| BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors Copanlisib, Elimusertib - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-22 | 2022-05-27 | |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Elimusertib - Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2021-12-22 | 2026-01-23 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-10-20 | 2026-09-10 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Cisplatin, Elimusertib, Gemcitabine Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2021-08-25 | 2026-07-31 |
| Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 10 | 2021-08-13 | 2026-08-21 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2021-06-01 | 2026-07-31 |
Lung Neoplasms (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Carcinoma (1) · Carcinoma, Neuroendocrine (1) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Lymphoma (1) · Mesothelioma, Malignant (1) · Mouth Neoplasms (1) · Oropharyngeal Neoplasms (1) · Penile Neoplasms (1)
National Cancer Institute (NCI) (6) · M.D. Anderson Cancer Center (1)
United States (6) · Canada (2)
James M Cleary (1) · Liza C Villaruz (1) · Mamta Parikh (1) · Michael V Ortiz (1) · Thatcher Heumann (1) · Timothy A Yap, MD (1) · Yvonne M Mowery (1)
UM1CA186690 (2), UM1CA186689 (1), UM1CA186709 (1), UM1CA186717 (1), UM1CA228823 (1)